

IMMUNOBIOTIC PORTFOLIO

The Imunolak portfolio

Microbiome science for immune support.

A range of carefully developed formulations, bringing an immunobiotic approach to everyday use from infancy through adulthood.



Four formulations.
A distinct partner opportunity.

Four formulations, across life stages.

A focused range for distinct needs, united by the microbiome.



Imunolak Baby

ORAL DROPS

From the first day of life

30 doses

Microbiota support in the earliest stage of life.



Imunolak

ORIGINAL FORMULA

5 billion bacteria

30 capsules

The foundation of the Imunolak range, for children aged 3+ and adults.



Imunolak Kids

D3 + Zn

3 billion bacteria

D3 1,200 IU + zinc 7 mg

30 capsules | Age 3+

A formulation combining probiotics with vitamin D3 and zinc.



Imunolak Adults

D3 + Zn

5 billion bacteria

D3 2,700 IU + zinc 12 mg

30 capsules | Adults

Probiotics with vitamin D3 and zinc, formulated for adults.

Hypro-ri® zinc: Imunolak Kids and Adults contain zinc in the Hypro-ri® form, a patented ingredient designed for improved zinc bioavailability.

Explore the range at www.imunolak.com

Product information: current Imunolak portfolio and supplied packaging. Figures shown are formulation and pack details.

A considered addition to your portfolio.

Imunolak offers distributors a defined brand proposition, a focused product range and materials to support professional communication.

01 A clear category position

An immunobiotic concept centred on microbiome modulation and immune support gives partners a specific story to communicate.

02 A differentiated range

Four formulations help partners address different life stages within one recognisable product family.

03 A basis for professional dialogue

Published research provides a basis for informed discussions with pharmacists and healthcare professionals. Selected references appear overleaf.

04 Adaptable market communication

The portfolio allows partners to shape communication around local audiences and everyday or seasonal immune-support needs.

05 Education and launch support

Brand identity, educational materials and sales-team training form part of the Save Health Microbiome partner proposition.

Science behind the conversation.

Selected research explores microbiome modulation in fragile X syndrome, rheumatoid arthritis and childhood atopic dermatitis. These publications provide context for professional evaluation of the studied formulations.

SELECTED PUBLICATIONS

01 Microbiome modulation in fragile X syndrome

Protic D, Bascarevic D, Dimitrijevic S, et al. Microbiome modulation and behavioural improvements in children with fragile X syndrome following probiotic intake: A pilot study. Scientific Reports. 2026;16:560.

doi: 10.1038/s41598-025-29896-1

02 Immunobiotics in rheumatoid arthritis

Barac B, Lukovic S, Kojic T, Radnic TZ, Bibic A. Therapeutical efficacy of immunobiotics in patients with newly diagnosed rheumatoid arthritis. Journal of Infection in Developing Countries. 2025;19:1861-1868.

doi: 10.3855/jidc.21182

03 Probiotics with vitamin D3 and zinc in atopic dermatitis

Filipovic I, Ostojic O, Vekovic V, Mihajlovic S, Caminati M, Zivkovic Z. Efficacy of Specially Formulated Combination Three Probiotic Strains with Vitamin D3 and Zn in Children with Atopic Dermatitis. American Journal of Pediatrics. 2023;9(4):186-192.

doi: 10.11648/j.ajp.20230904.11

Findings relate to the formulations and populations studied; they should not be generalised to every product in the range.

Let's discuss your market.

Save Health Microbiome

www.imunolak.com

www.shmicrobiome.com



IMUNOLAK



SHM